MoonLake Immunotherapeutics

Yahoo Finance • 16 days ago

MoonLake Immunotherapeutics GAAP EPS of -$0.98 misses by $0.07

* MoonLake Immunotherapeutics press release [https://seekingalpha.com/pr/20508432-moonlake-immunotherapeutics-announces-positive-outcome-from-its-final-pre-bla-meeting-with] (MLTX [https://seekingalpha.com/symbol/MLTX]): Q1 GAAP EPS of -$... Full story

Yahoo Finance • 17 days ago

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the label strategy for sonelokimab (SLK) in hi... Full story

Yahoo Finance • last month

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?

Chief Executive Officer Jorge Santos da Silva reported the sale of 150,000 shares of MoonLake Immunotherapeutics(NASDAQ:MLTX) through multiple open-market transactions on April 10, 2026 and April 13, 2026, according to a SEC Form 4 filing.... Full story

Yahoo Finance • 2 months ago

Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares

Key Points BVF sold 3,750,000 shares for a transaction value of approximately $62.96 million on April 2, 2026. The sale represented 78.30% of BVF's direct holdings, reducing direct ownership to 1,039,238 shares. All shares were sold from... Full story

Yahoo Finance • 2 months ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR7... Full story

Yahoo Finance • 2 months ago

Micron downgraded, Five Below upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: William Blair upgraded Five Below(FIVE... Full story

Yahoo Finance • 3 months ago

Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline Update

MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update MoonLake I... Full story

Yahoo Finance • 3 months ago

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently, other clinical and imaging scores also s... Full story

Yahoo Finance • 4 months ago

Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. MoonLake Immunotherapeutics is the next stock on our list. TheFly reported on January 14 that Goldman Sachs downgraded MLTX to Sell from Neutral and set a pri... Full story

Yahoo Finance • 5 months ago

DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 5 months ago

Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors

LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises MoonLake Immunotherapeutics, Inc., (“MoonLake” or the "Company") (NASDAQ: MLTX) investors of a class action on behalf of investors that bought securities between... Full story

Yahoo Finance • 5 months ago

MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Dec. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics (... Full story

Yahoo Finance • 5 months ago

MLTX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action – MLTX

NEW YORK, Dec. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dat... Full story

Yahoo Finance • 5 months ago

MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

SAN FRANCISCO, Dec. 13, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is... Full story

Yahoo Finance • 5 months ago

MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options If you purchased or acquired MoonLake Immunotherapeutics common sto... Full story

Yahoo Finance • 5 months ago

MLTX FRAUD UPDATE: Important MoonLake Immunotherapeutics Securities Fraud Class Action Deadline is Approaching for Investors – Contact BFA Law before December 15

NEW YORK, Dec. 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives... Full story

Yahoo Finance • 5 months ago

MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MLTX

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks t... Full story

Yahoo Finance • 5 months ago

Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against MoonLake Immunotherapeutics (MLTX), DexCom, Inc. (DXCM), and Synopsys, Inc. (SNPS)

ATLANTA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: MoonLake Immunotherapeutics (MLTX) The shareholder class a... Full story

Yahoo Finance • 5 months ago

DEADLINE ALERT for MLTX, BAX, JHX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • 5 months ago

MLTX 4-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is... Full story